Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 2,801–2,900 of 3,636
Neues beim Schlaganfall – Teil 2: Prävention
Diener, H., Endres, M., Fiehler, J., Gerloff, C. P., Häusler, H. G., Kuramatsu, J. B., Pfeilschifter, W., Poli, S., Purrucker, J. C., Schnabel, R. B., et al. (2021) · Neurologie up2date · doi:10.1055/a-1163-6514 · Cited by 1
Prevenzione secondaria nella malattia coronarica
Sorbets, E., Lallmahomed, E., Kretz, S., Cinaud, A., Vallée, A., Lelong, H., Blachier, V., & Blacher, J. (2021) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(21)44575-4 · Cited by 1
Addressing Nutritional Gaps: Simple Steps for the Primary Care Provider
Quan, Q. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0059 · Cited by 1
An Individualized, Case-Based Approach to the Management of Irritable Bowel Syndrome
Lacy (2020) · The Journal of Family Practice · doi:10.12788/jfp.0060 · Cited by 1
Ischemic Heart Disease: Case Report
Thakare, P. (2020) · Indian Journal of Forensic Medicine & Toxicology · doi:10.37506/ijfmt.v14i4.12649 · Cited by 1
Alirocumab in Post ACS Patients - Saving Lives at a Premium
George, M., & Goenka, L. (2021) · Current Cardiology Reviews · doi:10.2174/1573403x17666210603111158 · Cited by 1
“The result of the ODYSSEY outcome study has been published [1].”
BackgroundChaulin, A. M. (2021) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf19137-46 · Cited by 2
Biologic therapy for dyslipidemia
Karásek, D. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.054 · Cited by 2
Zavrtanik, M., Likozar, A. R., & Šebeštjen, M. (2021) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3057
Atherosclerotic cardiovascular diseases and clinical significance of treatment with inclisiran
Blaha, V. (2021) · Klinická farmakologie a farmacie · doi:10.36290/far.2021.011 · Cited by 1
“Upraveno podle (16) Inclisiran (ORION Meta-Analysis) Alirocumab (ODYSSEY Outcomes) Evolocumab (FOURIER) Reakce v místě vpichu injekce 3,1 % (inclisiran) vs. 0,1 % (placebo); RR: 27,8 (95 % CI: 6,8–113,9) 3,8 % (alirocumab) vs. 2,1 % (placebo) (p < 0,001) 2,1 % (evolocumab) vs. 1,6 % (placebo) Bronchitida 4,3 % (inclis…”
Aronow, W. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.87280 · Cited by 1
Decision Points in the Management of Patients with Diabetic Kidney Disease
Weir (2021) · The Journal of Family Practice · doi:10.12788/jfp.0217 · Cited by 1
Utilizing CGM Ambulatory Glucose Profiles to Optimize Diabetes Management
Miller (2021) · The Journal of Family Practice · doi:10.12788/jfp.0226 · Cited by 2
Tsai, C.-L., Chang, Y.-H., Su, C., Wu, Y., Yeh, H., & Lin, C. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.11.007 · Cited by 2
Welche Risikofaktoren gibt es und was kann man dagegen tun?
Hambrecht, R., & Wienbergen, H. (2021) · Springer eBooks · doi:10.1007/978-3-662-63467-7_2 · Cited by 1
Wagner, J. R., Fitzpatrick, J. K., Yang, J., Sung, S. H., Allen, A., Philip, S., Granowitz, C. B., Abrahamson, D., Ambrosy, A. P., & Go, A. S. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100319 · Cited by 1
“High-intensity 41,141 (11) 12,255 (12) 6102 (12) 4703 (11) 18,081 (10) Unknown 5 (0) 2 (0) 2 (0) 0 (0) 1 (0) Non-statin lipid lowering agent, N (%) 18,927 (5) 4394 (4) 3020 (5) 2508 (6) 9005 (6)”
Trendi v sekundarni preventivi po srčnem infarktu – umestitev novosti
Veselič, M. T., & Šabović, M. (2022) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3169 · Cited by 1
Management of Hypercholesterolaemia for Cardiovascular Risk Reduction: A Malaysian Perspective
Rajadurai, J., Ahmad, W. A. W., Nawawi, H. M., Choo, G.-H., Kiat, N. W., Ali, R. M., Omar, A. F., Kasim, S. S., & Quek, D. K. (2022) · Acta Scientific Medical Sciences · doi:10.31080/asms.2022.06.1260
Anastasiou, G., Liamis, G. L., Milionis, H. J., Elisaf, M., Christopoulou, E. C., Dimitriou, T., & Liberopoulos, E. N. (2020) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1006 · Cited by 1
Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia
Hughes-Hubley, F., Iskander, M., Cheng-Lai, A., Frishman, W. H., & Nawarskas, J. J. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000452 · Cited by 1
Smetana, G. W., Benson, M. D., Juraschek, S. P., & Burns, R. B. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0908 · Cited by 1
Management of Dyslipidemia after Stroke
Chang, Y., & Song, T. (2022) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2022.3.1 · Cited by 1
Gerő, L. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.11
ORION-3: delivering lipid lowering treatment for longer
Nicholls, S. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00362-x · Cited by 2
Therapy of Elevated Lipoprotein(a)
Ibrahim, S., & Stroes, E. S. G. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_21 · Cited by 2
Conde, C. B., Martínez, N. R., Ibarbia, C. G., Guerra-Ruiz, A. R., Miguel, I. O., Belaustegui, M. C., Lavín, B. A., Vilchez, F. J. G., Hernández, J. M. D. L. T., & Hernández, J. L. (2023) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2023.02.011 · Cited by 3
Conde, C. B., Martínez, N. R., Ibarbia, C. G., Guerra-Ruiz, A. R., Miguel, I. O., Belaustegui, M. C., Lavín, B. A., Vilchez, F. J. G., Hernández, J. M. D. L. T., & Hernández, J. L. (2023) · Revista Clínica Española · doi:10.1016/j.rce.2023.02.001 · Cited by 1
Lipide: Diagnostik und Therapie bei Diabetes mellitus (Update 2023)
Wascher, T. C., Paulweber, B., Toplak, H., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02166-8 · Cited by 1
Secondary Prevention of Coronary Heart Disease and PCSK9 Inhibitors
Andrey, K. (2021) · Advances in Pharmacology & Clinical Trials · doi:10.23880/apct-16000187
Thuốc Ức chế PCSK9 trong Hội chứng mạch vành cấp: Hiện trạng và triển vọng lâm sàng
Thanh, H. T. (2023) · Tạp chí Tim Mạch Học Việt Nam · doi:10.58354/jvc.106.2023.484
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 4
Attanasio, M., & Santanna, M. (2021) · Endocrinology Diabetes and Obesity · doi:10.31532/endocrinoldiabetesobes.2.1.002 · Cited by 1
The Cat Has 9 Lives, Until it Dies
Genest, J. J., & Nguyen, D.-V. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.025 · Cited by 1
Statistical testing in a Linear Probability SpacePreprint
Rembold, C. M. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1904.01491 · Cited by 2
ERKRANKUNGEN DER ENDOKRINEN ORGANE UND DES STOFFWECHSELS
Jung, N., Mayet, W.-J., Mertens, P. R., Meyer, J. S., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C.-M. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50015-2 · Cited by 1
Giallauria, F. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001150 · Cited by 1
Barradas‐Pires, A., Alcazar, M. D., Martínez‐Rubio, A., & Dimopoulos, K. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa140 · Cited by 2
Atherosclerosis: Cholesterol Management
Edmondson, S. D., Burnett, D. A., & Davis, H. R. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc185.pub2 · Cited by 1
“Alirocumab performed similarly well in the large ODYSSEY CVOT with 18 924 subjects with recent acute coronary syndrome on a background of high-intensity statin therapy [194].”
MethodThe Enigma of PCSK9 Regulation
Goonewardena, S. N., & Rosenson, R. S. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.006 · Cited by 1
Future Energy Supply, Simulations with Limited Resources
Benichou, L. (2011) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Secondary Prevention of Atherosclerotic Cardiovascular Disease
Power, D., & Rosenson, R. S. (2022) · Interventional Cardiology · doi:10.1002/9781119697367.ch44 · Cited by 1
Knock down of PCSK9 can improve myocardial ischemia/reperfusion injury by inhibiting autophagyPreprint
Huang, G., Lu, X., Duan, Z., Zhang, K., Xiong, X., Lin, M., Li, C., Li, Y., Xu, L., Zhou, H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1610254/v1 · Cited by 1
Zhu, W., Huang, P., Li, R., Ran, J., Dai, W., Tang, Y., Lian, P., Ding, C., & Huang, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1890507/v1 · Cited by 1
The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022
Martin, A. K., Feinman, J. W., Bhatt, H. V., Fritz, A. V., Subramani, S., Malhotra, A. K., Townsley, M. M., Sharma, A., Patel, S. J., Ha, B., et al. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2022.11.002 · Cited by 1
Xiao, J., Zhang, S., Shu, H., Chen, X., Zhou, L., Shang, K., Qin, C., Xu, W., & Tian, D. (2023) · Research Square · doi:10.21203/rs.3.rs-2038721/v1 · Cited by 1
Prevention of Coronary Atherosclerosis
Figtree, G. A., Kott, K. A., & Vernon, S. T. (2023) · Springer eBooks · doi:10.1007/978-3-031-25879-4_3 · Cited by 1
Geographic and ethnic variations in response to lipid-lowering therapies: why do they matter?
Aikawa, T. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad114 · Cited by 2
Chou, O. H. I., Li, L., Chung, C. T., Lü, L., Lee, Q., Pui, H. H. H., Leung, B. K. H., Chang, C., Liu, T., Wai, A. K. C., et al. (2023) · medRxiv · doi:10.1101/2023.09.23.23296003 · Cited by 1
Xanthomas and Abnormalities of Lipid Metabolism and Storage
Flynn, P. D. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook060 · Cited by 1
Luo, S., Lin, L., Qiu, P., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4604642/v1 · Cited by 1
Lipoprotein(a) is Associated with Increased Low-Density Plaque VolumePreprint
Fisher, R., Nurmohamed, N. S., Fisher, E. A. A., Aquino, M. B., Earls, J. P., Min, J. K., Gurevitz, C., Malick, W. A., Peters, M. R., Goonewardena, S. N., et al. (2024) · medRxiv · doi:10.1101/2024.07.18.24310539 · Cited by 1
Bhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendera, K., Taha, A., Nadarajah, R., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5116096 · Cited by 1
Self-citationWhen PCSK9 Inhibitors Don’t Save the Day
Soffer, D. E. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.103759 · Cited by 1
Reconciling Coronary Artery Calcification in the Lipid-Lowering Era
Khanna, S., Nerlekar, N., & Bhat, A. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102506 · Cited by 2
Oduah, E. I., Zhang, T., Jung, S.-H., Stinchcombe, T. E., Ready, N., Crawford, J., Clarke, J. M., Gray, J. E., & Antonia, S. J. (2026) · Future Oncology · doi:10.1080/14796694.2026.2648863 · Cited by 1
PharmacotherapyFirst: A Multimedia Learning Resource
Munyer, T. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst
Drugs that affect lipid metabolism
Tran, R. J. C., & Phoenix, A. (2019) · Side effects of drugs annual · doi:10.1016/bs.seda.2019.08.004 · Cited by 1
Krychtiuk, K. A., & Speidl, W. S. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318820977
Periphere arterielle Verschlusskrankheit: Wann ist ein PCSK9-Inhibitor sinnvoll?
Kröger, K., Espinola–Klein, C., Hoffmann, U., Kalka, C., Lawall, H., & Weiss, N. (2018) · Gefäßmedizin Scan - Zeitschrift für Angiologie Gefäßchirurgie diagnostische und interventionelle Radiologie · doi:10.1055/a-0774-4494
Shader, R. I. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.12.011
High intensity lipid‐lowering therapy after acute coronary syndromes: room for improvement
Kostner, K. (2018) · The Medical Journal of Australia · doi:10.5694/mja2.12055
Perrot, N., Moschetta, D., Boekholdt, S. M., Valerio, V., Martinsson, A., Capoulade, R., Mass, E., Clavel, M.-A. A., Wareham, N. J., Dina, C., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/560458
“PCSK9 inhibitors have been shown to substantially lower LDL-C levels in various populations and reduce the risk of adverse cardiovascular outcomes in patients at high cardiovascular risk (10,11).”
BackgroundDon’t stop at statins: complementary PCSK9 use in patients at high risk for recurrent cardiac events
Grodzinsky, A., Pokharel, Y., & Myadam, R. (2019) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcz013
Harada‐Shiba, M. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.03.003
Selección de lo mejor del año 2018 en riesgo vascular y rehabilitación cardiaca
Frías, P. T., Ruíz, R. C., Duque, J. A. A., Senén, A. B., Olmo, M. R. F., & Jiménez, M. A. (2019) · REC CardioClinics · doi:10.1016/j.rccl.2019.01.007 · Cited by 2
Ökonomische Überlegungen zur medikamentösen Lipidsenkung
Schlögl, H. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0469-5
Singh, A. (2019) · Heart India · doi:10.4103/heartindia.heartindia_10_19
Baseline LDL-C levels and risk of cardiovascular events: is there any room for questions?
Rocha, V. Z., & Santos, R. D. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.03.058
Emerging Lipid-Lowering Therapies in Secondary Prevention
Mahtta, D., Virani, S. S., & Bavry, A. A. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0607-z
Thomas, D. G. (2019) · Columbia Academic Commons (Columbia University) · doi:10.7916/d8-5wc2-4f04
Nuovi farmaci ipolipemizzanti: anticorpi monoclonali inibitori di PCSK9
Scicali, R., Pino, A. D., Piro, S., Rabuazzo, A. M., & Purrello, F. (2019) · L Endocrinologo · doi:10.1007/s40619-019-00575-4
“462 pazienti vennero tratati con alirocumab 75 mg somministrato ogni due settimane [13].”
BackgroundFrom the last EuroPrevent towards the first ESC Preventive Cardiology Congress
Castelletti, S., & Adami, P. E. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319853330
Editorial commentary: Using PCSK9 inhibitors to win at “cholesterol limbo”
Thompson, P. D. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.06.003
After an acute coronary syndrome, alirocumab reduced total nonfatal CV events and deaths vs placebo
Bates, E. (2019) · Annals of Internal Medicine · doi:10.7326/acpj201906180-062
Pintó, X., & Sarasa, I. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.05.005 · Cited by 2
Mortality reduction with PCSK9 inhibition: A case of cautious optimism
Dixon, D. L., & Virani, S. S. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.06.012
General Discussion and Future Perspectives
Cassarini, C. (2019) · CRC Press eBooks · doi:10.1201/9780429448300-7
van Bruggen, F. H. (2019) · Huisarts en Wetenschap · doi:10.1007/s12445-019-0256-y
Exploratory “Odyssey” During Pursuit of Plaque Control
Ando, H., Takashima, H., & Amano, T. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0754
Introduction to translational research in vascular surgery/medicine
Atturu, G., & Gooneratne, T. (2019) · Indian Journal of Vascular and Endovascular Surgery · doi:10.4103/ijves.ijves_30_19
Preventive cardiology: what the interventional cardiologist needs to know in 2019
McEvoy, J. W., & Mylotte, D. (2019) · EuroIntervention · doi:10.4244/eijv15i5a70
Insights on the efficacy and safety of PCSK-9 inhibitor in Taiwanese patients
Chen, H.-S. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000183
High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?
Nelson, A. J., Mirzaee, S., & Nicholls, S. J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00363-3
Novel Therapies for Dyslipidemia
Tafaj-Reddy, O. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88477
Clinical characteristics and prognosis of patients with angina pectoris and heart failure
Badar, A. (2019) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.75073 · Cited by 1
Encouragement of Super-aggressive LDL-lowering Therapies
Tada, H., Sakata, K., Takamura, M., & Kawashiri, M. (2019) · Journal of Coronary Artery Disease · doi:10.7793/jcad.25.19-00005
Finneran, P., Sanborn, T., Guo, X., Traynor, K., Jaff, M. R., & Natarajan, P. (2019) · medRxiv · doi:10.1101/2019.12.11.19014399
Shalnev, V. I. (2019) · EMERGENCY MEDICAL CARE · doi:10.24884/2072-6716-2019-0-3-62-67
Wang, T., Wang, K.-L., & Chiang, C. (2019) · Europe PMC (PubMed Central) · doi:10.6515/acs.201911_35(6).20191028a
Sánchez Vega, J. D., & Zamorano Gómez, J. L. (2019) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.34.3.27 · Cited by 1
Ruiz, S. P., Parra‐Virto, A., do Rego, A. T., Rodríguez, P. D., & Álvarez-Sala, J. L. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.04.002
2. Pathophysiology of Atherosclerosis and Its Prevention and Treatment
Yamashita, S. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.1685
Ennezat, P. V., Guerbaaï, R.-A., & Jemtel, T. H. L. (2020) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2019-111242 · Cited by 2
Writers, A. M. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00714-0
Канорский, С. Г. (2020) · Kardiologiia · doi:10.18087/cardio.2020.2.n943
Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
Gimadeeva, A., Galyavich, A. S., Галеева, З. М., et al. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-2-3724
Lipide und PCSK9-Inhibition bei chronischer Nierenerkrankung
Schunk, S. J., Fliser, D., & Speer, T. (2020) · Der Nephrologe · doi:10.1007/s11560-020-00421-x
Hyperlipidemia management in Slovakia: observational study
Fábryová, Ľ., & Nemcová, A. (2019) · Vnitřní lékařství · doi:10.36290/vnl.2019.133 · Cited by 1
“Dôležité je spomenúť, že dlhodobé údaje týkajúce sa KV cieľových ukazovateľov zo štúdií FOURIER a ODYSSEY potvrdzujú, že evolokumab [32] a alirokumab [34] významne znižujú výskyt KV príhod.”
Gao, H., Yang, C., Yang, J., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.015
Lscher, T. F., Gallino, A., Haegeli, L., Kobza, R., Koskinas, K. C., Miserez, A., Nanchen, D., Noll, G., Pedrazzini, G. B., Rber, L., et al. (2020) · Cardiovascular Medicine · doi:10.4414/cvm.2020.02102
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

